Randomized Study of the Effect of Decreased Hyperinsulinemia on the Ovulatory Response to Clomiphene Citrate in Obese Women With Polycystic Ovary Syndrome
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
OBJECTIVES:
I. Determine whether reduction of serum insulin levels by metformin increases ovulatory response to clomiphene or spontaneous ovulation in obese women with polycystic ovary syndrome.
| Condition | Intervention |
|---|---|
|
Hyperinsulinism Polycystic Ovary Syndrome |
Drug: clomiphene citrate Drug: metformin |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Masking: Double-Blind Primary Purpose: Treatment |
| Estimated Enrollment: | 88 |
| Study Start Date: | January 2000 |
PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, multicenter study. Patients are randomized to one of two treatment arms.
Patients receive oral metformin (arm I) or oral placebo (arm II) three times daily for 8 weeks. All patients who do not ovulate by day 28 receive oral clomiphene citrate daily on days 36-40.
Eligibility| Ages Eligible for Study: | 18 Years to 40 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
Obese women with chronic anovulation due to polycystic ovary syndrome (PCOS)
Must have oligoamenorrhea and hyperandrogenemia
--Prior/Concurrent Therapy--
At least 2 months since prior standard therapy (including over the counter drugs) At least 2 months since prior investigational agents
--Patient Characteristics--
Hematopoietic: Hematocrit greater than 38%
Hepatic: Liver function normal No clinically significant hepatic disease
Renal: No clinically significant renal disease Creatinine less than 1.4 mg/dL No proteinuria
Cardiovascular: No clinically significant cardiac disease
Pulmonary: No clinically significant pulmonary disease
Hormonal: Thyroid function normal Prolactin normal Fasting 17 alpha-hydroxy progesterone less than 200 mg/dL OR No late onset adrenal hyperplasia 21 alpha-hydroxylase deficiency
Other: Not pregnant Negative pregnancy test Fertile patients must use effective contraception No diabetes mellitus No clinically significant neurologic, psychiatric, infectious, neoplastic, or metabolic disease No clinically significant malignant disease except nonmelanomatous skin cancer At least 1 year since any prior drug abuse or alcoholism
Contacts and Locations More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00005654 History of Changes |
| Other Study ID Numbers: | 199/14914, UVA-WSE023 |
| Study First Received: | May 2, 2000 |
| Last Updated: | June 23, 2005 |
| Health Authority: | United States: Federal Government |
Keywords provided by Office of Rare Diseases (ORD):
|
endocrine disorders hyperinsulinism polycystic ovarian syndrome rare disease |
Additional relevant MeSH terms:
|
Hyperinsulinism Polycystic Ovary Syndrome Glucose Metabolism Disorders Metabolic Diseases Ovarian Cysts Cysts Neoplasms Ovarian Diseases Adnexal Diseases Genital Diseases, Female Gonadal Disorders Endocrine System Diseases Clomiphene |
Metformin Estrogen Antagonists Estrogen Receptor Modulators Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Pharmacologic Actions Fertility Agents, Female Fertility Agents Reproductive Control Agents Therapeutic Uses Selective Estrogen Receptor Modulators Hypoglycemic Agents |
ClinicalTrials.gov processed this record on May 19, 2013